Glyxambi
Generic name: Empagliflozin And Linagliptin
Drug class:
Antidiabetic combinations
Usage of Glyxambi
Glyxambi contains a combination of empagliflozin and linagliptin. Empagliflozin and linagliptin are oral diabetes medicines that help control blood sugar levels. Empagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Linagliptin works by regulating the levels of insulin your body produces after eating.
Glyxambi is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Glyxambi is also used to lower the risk of death from heart attack, stroke, or heart failure in adults with type 2 diabetes who also have heart disease.
This medicine is not for treating type 1 diabetes.
Glyxambi side effects
Get emergency medical help if you have signs of an allergic reaction to Glyxambi: hives, itching, flaking or peeling skin; trouble swallowing, difficult breathing; swelling of your face, lips, tongue, or throat.
Seek medical attention right away if you have signs of a serious genital infection (penis or vagina): burning, itching, odor, discharge, pain, tenderness, redness or swelling of the genital or rectal area, fever, not feeling well. These symptoms may get worse quickly.
Stop taking Glyxambi and call your doctor at once if you have:
Stop taking this medicine and call your doctor at once if you have:
Common Glyxambi side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Glyxambi
You should not use Glyxambi if you are allergic to empagliflozin or linagliptin, or if you have:
To make sure Glyxambi is safe for you, tell your doctor if you have ever had:
Follow your doctor's instructions about using Glyxambi if you are pregnant or you become pregnant. Controlling diabetes is very important during pregnancy.
You should not use Glyxambi during the second or third trimester of pregnancy.
You should not breastfeed while using Glyxambi.
Relate drugs
- Actoplus Met
- Actoplus Met XR
- Alogliptin and metformin
- Alogliptin and pioglitazone
- Avandamet
- Avandaryl
- Canagliflozin and metformin
- Dapagliflozin and metformin
- Dapagliflozin and saxagliptin
- Duetact
- Empagliflozin and linagliptin
- Empagliflozin and metformin
- Empagliflozin, linagliptin, and metformin
- Ertugliflozin and metformin
- Ertugliflozin and sitagliptin
- Glimepiride and pioglitazone
- Glipizide and metformin
- Glucovance
- Glyburide and metformin
- Glyxambi
- Insulin degludec and liraglutide
- Insulin glargine and lixisenatide
- Invokamet
- Invokamet XR
- Janumet
- Janumet XR
- Jentadueto
- Jentadueto XR
- Kazano
- Kombiglyze XR
- Linagliptin and metformin
- Metaglip
- Metformin and pioglitazone
- Metformin and saxagliptin
- Metformin and sitagliptin
- Oseni
- Pioglitazone and glimepiride
- Pioglitazone and metformin
- PrandiMet
- Qtern
- Repaglinide and metformin
- Rosiglitazone and glimepiride
- Rosiglitazone and metformin
- Saxagliptin and dapagliflozin
- Saxagliptin and metformin
- Segluromet
- Sitagliptin and metformin
- Soliqua
- Soliqua 100/33
- Steglujan
- Synjardy
- Synjardy XR
- Trijardy XR
- Xigduo XR
- Xultophy
How to use Glyxambi
Usual Adult Dose of Glyxambi for Diabetes Type 2:
Initial dose: Empagliflozin 10 mg-linagliptin 5 mg orally once a day in the morning -For patients tolerating therapy, may increase to empagliflozin 25 mg-linagliptin 5 mg once a day Maximum dose: Empagliflozin 25 mg-linagliptin 5 mg per day Comments: -Not recommended in patients with type 1 diabetes mellitus as it may increase the risk of diabetic ketoacidosis in these patients. -Has not been studied in patients with a history of pancreatitis and it is not know whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis during therapy. -When used in combination with insulin or insulin secretagogues, a lower dose of the insulin secretagogues or insulin may be necessary to reduce the risk of hypoglycemia. Uses: -As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. -Empagliflozin is indicated to reduce the risk of cardiovascular death in patients with diabetes mellitus and established cardiovascular disease.
Warnings
You should not use Glyxambi if you have severe kidney disease (or if you are on dialysis) or diabetic ketoacidosis, or if you have ever had a severe allergic reaction to empagliflozin or linagliptin.
Call your doctor at once if you have signs of a serious side effect, such as severe pain in your upper stomach spreading to your back, vomiting, fast heart rate, dizziness, feeling very thirsty or hot, decreased urination, heavy sweating, or hot and dry skin.
In rare cases, Glyxambi can cause serious infections in the penis or vagina. Get medical help right away if you have burning, itching, odor, discharge, pain, tenderness, redness or swelling of the genital or rectal area, fever, or if you don't feel well.
What other drugs will affect Glyxambi
Other drugs may increase or decrease the effects of Glyxambi on lowering your blood sugar. Tell your doctor about all your current medicines and any you start or stop using, especially:
This list is not complete. Other drugs may interact with empagliflozin and linagliptin, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions